|
Characteristic
|
Diabetic group (n = 72) [%]
|
Non-diabetic group (n = 144) [%]
|
χ2
|
P value
|
|---|
|
T stage
|
|
T1
|
16 (22.2)
|
36 (25.0)
|
0.809
|
0.667
|
|
T2
|
35 (48.6)
|
74 (51.4)
| | |
|
T3
|
21 (29.2)
|
34 (23.6)
| | |
|
Axillary lymph nodes
|
|
Positive
|
45 (62.5)
|
75 (52.1)
|
2.109
|
0.146
|
|
Negative
|
27 (37.5)
|
69 (47.9)
| | |
|
Pathological types
|
|
Invasive ductal carcinoma
|
66 (91.7)
|
136 (94.4)
|
0.890
|
0.828
|
|
Invasive lobular carcinoma
|
3 (4.2)
|
3 (2.1)
| | |
|
Invasive papilloma
|
2 (2.8)
|
3 (2.1)
| | |
|
Mucinous adenocarcinoma
|
1 (1.4)
|
2 (1.4)
| | |
|
Tumor stage
|
|
I
|
4 (5.6)
|
19 (13.2)
|
2.966
|
0.227
|
|
II
|
27 (37.5)
|
51 (35.4)
| | |
|
III
|
41 (56.9)
|
74 (51.4)
| | |
|
Histological grade
|
|
WHO I
|
5 (6.9)
|
9 (6.2)
|
2.099
|
0.350
|
|
WHO II
|
42 (58.3)
|
98 (68.1)
| | |
|
WHO III
|
25 (34.7)
|
37 (25.7)
| | |
|
Lymph node metastasis
|
|
Positive
|
45 (62.5)
|
55 (38.2)
|
11.410
|
<0.001
|
|
Negative
|
27 (37.5)
|
89 (61.8)
| | |
|
ER
|
|
Positive
|
42 (58.3)
|
88 (61.1)
|
0.155
|
0.694
|
|
Negative
|
30 (41.7)
|
56 (38.9)
| | |
|
PR
|
|
Positive
|
40 (55.6)
|
91 (63.2)
|
1.174
|
0.279
|
|
Negative
|
32 (44.4)
|
53 (36.8)
| | |
|
Her-2
|
|
Positive
|
25 (34.7)
|
66 (458)
|
2.431
|
0.119
|
|
Negative
|
47 (65.3)
|
78 (54.2)
| | |
|
P-gp
|
|
Positive
|
60 (83.3)
|
121 (84.0)
|
0.017
|
0.896
|
|
Negative
|
12 (16.7)
|
23 (16.0)
| | |
|
Topo-II
|
|
Positive
|
64 (88.9)
|
132 (91.7)
|
0.441
|
0.507
|
|
Negative
|
8 (11.1)
|
12 (8.3)
| | |
|
Gst-π
|
|
Positive
|
39 (54.2)
|
70 (48.6)
|
0.593
|
0.441
|
|
Negative
|
33 (45.8)
|
74 (51.4)
| | |
- Diabetic group, breast cancer patients with type 2 diabetes mellitus; non-Diabetic group, breast cancer patients without type 2 diabetes mellitus
-
WHO World Health Organization, ER estrogen receptor, PR progesterone receptor, Her-2 human epithelial growth factor receptor 2, P-gp P-glyprotein, Topo-II topoisomerase II, Gst-π glatocnine-S-tranferase-π
